Q1 2026 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2026-05-15 · accession 0001172661-26-002272
$435.1M
Reported value
42
Positions
2026-03-31
Period end
The Brief · GREAT POINT PARTNERS LLC · Q1 2026
AI · grounded in 13F
GREAT POINT PARTNERS LLC established a new position in IBRX worth $23.02M. The fund also opened new stakes in SOL-GEL TECHNOLOGIES LTD for $21.74M and ALUMIS INC for $18.86M. On the sell side, the fund closed its positions in DISC MEDICINE INC and RAPT, reducing exposure by $19.85M and $19.68M respectively. Additionally, the fund increased its holding in NKTR by 50.17%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $31.5M | 7.23% | 374,000 | Common | SHARED |
| 929033207 | VOR | VOR BIOPHARMA INC | $31.2M | 7.18% | 1,750,000 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $25.1M | 5.77% | 4,215,930 | Common | SHARED |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $24.3M | 5.59% | 1,750,000 | Common | SHARED |
| 45256X103 | IBRX | IMMUNITYBIO INC | $23.0M | 5.29% | 3,000,800 | PUT | SHARED |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $22.8M | 5.23% | 316,453 | Common | SHARED |
| M8694L137 | SLGL | SOL-GEL TECHNOLOGIES LTD | $21.7M | 5.00% | 274,363 | Common | SHARED |
| 022307102 | ALMS | ALUMIS INC | $18.9M | 4.33% | 856,061 | Common | SHARED |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $16.1M | 3.69% | 220,000 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $13.8M | 3.18% | 2,500,000 | Common | SHARED |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $13.6M | 3.12% | 675,000 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $13.6M | 3.11% | 545,625 | Common | SHARED |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $13.6M | 3.11% | 964,462 | Common | SHARED |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $10.5M | 2.40% | 800,198 | Common | SHARED |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $10.2M | 2.35% | 524,066 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $10.1M | 2.32% | 500,000 | Common | SHARED |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $9.3M | 2.14% | 500,000 | Common | SHARED |
| 28658R106 | CLYM | CLIMB BIO INC | $9.1M | 2.10% | 1,334,130 | Common | SHARED |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $9.0M | 2.07% | 183,330 | Common | SHARED |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $8.7M | 2.00% | 1,200,000 | Common | SHARED |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $8.0M | 1.84% | 199,348 | Common | SHARED |
| 30054Y107 | EVMN | EVOMMUNE INC | $7.5M | 1.72% | 325,000 | Common | SHARED |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $7.4M | 1.70% | 300,000 | Common | SHARED |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $7.1M | 1.64% | 1,350,000 | Common | SHARED |
| 811292200 | SCYX | SCYNEXIS INC | $6.9M | 1.59% | 7,554,347 | Common | SHARED |
| 696389402 | PALI | PALISADE BIO INC | $6.0M | 1.37% | 3,405,757 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $5.9M | 1.35% | 2,238,496 | Common | SHARED |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $5.9M | 1.35% | 842,106 | Common | SHARED |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $5.4M | 1.24% | 1,020,489 | Common | SHARED |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $5.2M | 1.20% | 796,558 | Common | SHARED |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $5.2M | 1.20% | 327,307 | Common | SHARED |
| 74346M505 | PMN | PROMIS NEUROSCIENCES INC | $4.7M | 1.08% | 371,402 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $4.3M | 0.98% | 300,000 | Common | SHARED |
| 45258H106 | IMMX | IMMIX BIOPHARMA INC | $3.2M | 0.73% | 350,000 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $2.9M | 0.67% | 951,809 | Common | SHARED |
| N69605108 | PHVS | PHARVARIS N V | $2.3M | 0.54% | 82,800 | Common | SHARED |
| 44486Q103 | HUMA | HUMACYTE INC | $2.3M | 0.52% | 3,750,000 | Common | SHARED |
| 363225202 | GALT | GALECTIN THERAPEUTICS INC | $2.2M | 0.51% | 800,000 | CALL | SHARED |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $1.9M | 0.43% | 124,666 | Common | SHARED |
| G01767105 | ALKS | ALKERMES PLC | $1.8M | 0.41% | 50,000 | Common | SHARED |
| 032797300 | AVXL | ANAVEX LIFE SCIENCES CORP | $1.6M | 0.37% | 521,300 | CALL | SHARED |
| 67577R102 | IRD | OPUS GENETICS INC | $1.5M | 0.34% | 324,340 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.